Does the media prefer AMGN or BMY?

In the previous week, Bristol Myers Squibb had 10 more articles in the media than Amgen. MarketBeat recorded 50 mentions for Bristol Myers Squibb and 40 mentions for Amgen. Amgen's average media sentiment score of 1.30 beat Bristol Myers Squibb's score of 1.26 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 32 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bristol Myers Squibb 37 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to EXEL or BMY?

In the previous week, Bristol Myers Squibb had 44 more articles in the media than Exelixis. MarketBeat recorded 50 mentions for Bristol Myers Squibb and 6 mentions for Exelixis. Exelixis' average media sentiment score of 1.50 beat Bristol Myers Squibb's score of 1.26 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bristol Myers Squibb 37 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer BMY or GILD?

In the previous week, Gilead Sciences had 4 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 54 mentions for Gilead Sciences and 50 mentions for Bristol Myers Squibb. Gilead Sciences' average media sentiment score of 1.31 beat Bristol Myers Squibb's score of 1.26 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 37 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Gilead Sciences 45 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VRTX or BMY?

In the previous week, Bristol Myers Squibb had 15 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 50 mentions for Bristol Myers Squibb and 35 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.28 beat Bristol Myers Squibb's score of 1.26 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 26 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bristol Myers Squibb 37 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to ABBV or BMY?

In the previous week, AbbVie had 12 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 62 mentions for AbbVie and 50 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 1.26 beat AbbVie's score of 1.19 indicating that Bristol Myers Squibb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 49 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Bristol Myers Squibb 37 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Bristol Myers Squibb (BMY) Competitors

$54.10 +0.10 (+0.19%)

Closing price 06/18/2026 03:59 PM Eastern

Extended Trading

$54.07 -0.03 (-0.05%)

As of 06/18/2026 07:58 PM Eastern

Compare

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

Should you buy Bristol Myers Squibb stock or one of its competitors? MarketBeat compares Bristol Myers Squibb with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bristol Myers Squibb include Amgen (AMGN), Exelixis (EXEL), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and AbbVie (ABBV). These companies are all part of the "medical" sector.

How does Bristol Myers Squibb compare to Amgen?

Amgen (NASDAQ:AMGN) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Amgen has a net margin of 20.96% compared to Bristol Myers Squibb's net margin of 15.01%. Amgen's return on equity of 137.41% beat Bristol Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	20.96%	137.41%	13.28%
Bristol Myers Squibb	15.01%	64.87%	13.16%

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.0%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.7%. Amgen pays out 70.1% of its earnings in the form of a dividend. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years and Bristol Myers Squibb has raised its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen presently has a consensus price target of $354.42, suggesting a potential upside of 4.98%. Bristol Myers Squibb has a consensus price target of $61.31, suggesting a potential upside of 13.33%. Given Bristol Myers Squibb's higher possible upside, analysts plainly believe Bristol Myers Squibb is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	15 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.45
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37

76.5% of Amgen shares are held by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are held by institutional investors. 0.9% of Amgen shares are held by company insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Bristol Myers Squibb had 10 more articles in the media than Amgen. MarketBeat recorded 50 mentions for Bristol Myers Squibb and 40 mentions for Amgen. Amgen's average media sentiment score of 1.30 beat Bristol Myers Squibb's score of 1.26 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	32 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol Myers Squibb	37 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Amgen has higher earnings, but lower revenue than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	4.96	$7.71B	$14.37	23.49
Bristol Myers Squibb	$48.19B	2.29	$7.05B	$3.56	15.20

Amgen has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Summary

Amgen beats Bristol Myers Squibb on 15 of the 20 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Bristol Myers Squibb has higher revenue and earnings than Exelixis. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.62	$782.57M	$3.01	17.25
Bristol Myers Squibb	$48.19B	2.29	$7.05B	$3.56	15.20

Exelixis has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Exelixis currently has a consensus target price of $47.35, indicating a potential downside of 8.78%. Bristol Myers Squibb has a consensus target price of $61.31, indicating a potential upside of 13.33%. Given Bristol Myers Squibb's higher possible upside, analysts plainly believe Bristol Myers Squibb is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37

Exelixis has a net margin of 35.08% compared to Bristol Myers Squibb's net margin of 15.01%. Bristol Myers Squibb's return on equity of 64.87% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Bristol Myers Squibb	15.01%	64.87%	13.16%

In the previous week, Bristol Myers Squibb had 44 more articles in the media than Exelixis. MarketBeat recorded 50 mentions for Bristol Myers Squibb and 6 mentions for Exelixis. Exelixis' average media sentiment score of 1.50 beat Bristol Myers Squibb's score of 1.26 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Bristol Myers Squibb	37 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Exelixis beats Bristol Myers Squibb on 11 of the 17 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Gilead Sciences?

Bristol Myers Squibb (NYSE:BMY) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Gilead Sciences has lower revenue, but higher earnings than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.29	$7.05B	$3.56	15.20
Gilead Sciences	$29.44B	5.22	$8.51B	$7.34	16.86

Bristol Myers Squibb presently has a consensus target price of $61.31, suggesting a potential upside of 13.33%. Gilead Sciences has a consensus target price of $158.41, suggesting a potential upside of 28.00%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Gilead Sciences had 4 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 54 mentions for Gilead Sciences and 50 mentions for Bristol Myers Squibb. Gilead Sciences' average media sentiment score of 1.31 beat Bristol Myers Squibb's score of 1.26 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	37 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Gilead Sciences	45 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gilead Sciences has a net margin of 30.99% compared to Bristol Myers Squibb's net margin of 15.01%. Bristol Myers Squibb's return on equity of 64.87% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	15.01%	64.87%	13.16%
Gilead Sciences	30.99%	48.19%	18.28%

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by company insiders. Comparatively, 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.7%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.7%. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has raised its dividend for 17 consecutive years and Gilead Sciences has raised its dividend for 10 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Summary

Gilead Sciences beats Bristol Myers Squibb on 15 of the 19 factors compared between the two stocks.

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Vertex Pharmaceuticals currently has a consensus target price of $555.91, suggesting a potential upside of 23.09%. Bristol Myers Squibb has a consensus target price of $61.31, suggesting a potential upside of 13.33%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Vertex Pharmaceuticals is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37

In the previous week, Bristol Myers Squibb had 15 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 50 mentions for Bristol Myers Squibb and 35 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.28 beat Bristol Myers Squibb's score of 1.26 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	26 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol Myers Squibb	37 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has a net margin of 35.51% compared to Bristol Myers Squibb's net margin of 15.01%. Bristol Myers Squibb's return on equity of 64.87% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
Bristol Myers Squibb	15.01%	64.87%	13.16%

Bristol Myers Squibb has higher revenue and earnings than Vertex Pharmaceuticals. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	9.55	$3.95B	$16.86	26.79
Bristol Myers Squibb	$48.19B	2.29	$7.05B	$3.56	15.20

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vertex Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Summary

Vertex Pharmaceuticals beats Bristol Myers Squibb on 12 of the 16 factors compared between the two stocks.

How does Bristol Myers Squibb compare to AbbVie?

AbbVie (NYSE:ABBV) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

70.2% of AbbVie shares are held by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, AbbVie had 12 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 62 mentions for AbbVie and 50 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 1.26 beat AbbVie's score of 1.19 indicating that Bristol Myers Squibb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	49 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Bristol Myers Squibb	37 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

AbbVie currently has a consensus target price of $253.43, suggesting a potential upside of 16.99%. Bristol Myers Squibb has a consensus target price of $61.31, suggesting a potential upside of 13.33%. Given AbbVie's stronger consensus rating and higher possible upside, equities analysts plainly believe AbbVie is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37

Bristol Myers Squibb has a net margin of 15.01% compared to AbbVie's net margin of 5.79%. Bristol Myers Squibb's return on equity of 64.87% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	5.79%	-576.45%	13.39%
Bristol Myers Squibb	15.01%	64.87%	13.16%

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.2%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.7%. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. AbbVie has increased its dividend for 53 consecutive years and Bristol Myers Squibb has increased its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Bristol Myers Squibb has lower revenue, but higher earnings than AbbVie. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	6.26	$4.23B	$2.03	106.71
Bristol Myers Squibb	$48.19B	2.29	$7.05B	$3.56	15.20

AbbVie has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

Summary

AbbVie beats Bristol Myers Squibb on 12 of the 20 factors compared between the two stocks.

Get Bristol Myers Squibb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMY vs. The Competition

Export

Metric	Bristol Myers Squibb	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$110.27B	$3.41B	$6.43B	$23.21B
Dividend Yield	4.67%	2.32%	2.68%	4.06%
P/E Ratio	15.20	19.73	24.75	31.61
Price / Sales	2.29	320.10	530.01	112.15
Price / Cash	6.64	127.84	45.07	24.44
Price / Book	5.95	8.16	10.80	4.68
Net Income	$7.05B	$23.94M	$3.57B	$1.08B
7 Day Performance	-5.16%	2.57%	0.73%	-0.82%
1 Month Performance	-7.45%	2.35%	1.35%	1.61%
1 Year Performance	15.43%	55.09%	29.31%	24.87%

Bristol Myers Squibb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMY Bristol Myers Squibb	4.8259 of 5 stars	$54.10 +0.2%	$61.31 +13.3%	+15.5%	$110.27B	$48.19B	15.20	32,500	Positive News Dividend Announcement Gap Up High Trading Volume
AMGN Amgen	4.3487 of 5 stars	$354.06 +4.8%	$354.12 +0.0%	+16.6%	$182.28B	$36.75B	24.64	31,500	Positive News Analyst Forecast
EXEL Exelixis	2.9582 of 5 stars	$53.50 +1.7%	$47.35 -11.5%	+27.4%	$13.22B	$2.32B	17.77	1,077	Positive News Gap Up
GILD Gilead Sciences	4.9188 of 5 stars	$125.87 +3.6%	$156.93 +24.7%	+14.6%	$150.83B	$29.44B	17.15	17,000	Positive News Analyst Forecast Insider Trade
VRTX Vertex Pharmaceuticals	4.4623 of 5 stars	$445.04 +2.1%	$555.91 +24.9%	+0.7%	$110.59B	$12.00B	26.40	6,400	Positive News Analyst Upgrade Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BMY) was last updated on 6/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bristol Myers Squibb (BMY) Competitors

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

How does Bristol Myers Squibb compare to Amgen?

Summary

How does Bristol Myers Squibb compare to Exelixis?

Summary

How does Bristol Myers Squibb compare to Gilead Sciences?

Summary

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Summary

How does Bristol Myers Squibb compare to AbbVie?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY vs. The Competition

Bristol Myers Squibb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bristol Myers Squibb (BMY) Competitors

BMY vs. AMGN, EXEL, GILD, VRTX, and ABBV

How does Bristol Myers Squibb compare to Amgen?

Is AMGN or BMY more profitable?

Is AMGN or BMY a better dividend stock?

Do analysts prefer AMGN or BMY?

Do institutionals and insiders hold more shares of AMGN or BMY?

Does the media prefer AMGN or BMY?

Which has stronger earnings & valuation, AMGN or BMY?

Which has more volatility & risk, AMGN or BMY?

Summary

How does Bristol Myers Squibb compare to Exelixis?

Which has stronger valuation and earnings, EXEL or BMY?

Which has more volatility & risk, EXEL or BMY?

Do analysts rate EXEL or BMY?

Is EXEL or BMY more profitable?

Does the media refer more to EXEL or BMY?

Do institutionals and insiders have more ownership in EXEL or BMY?

Summary

How does Bristol Myers Squibb compare to Gilead Sciences?

Which has preferable earnings and valuation, BMY or GILD?

Do analysts prefer BMY or GILD?

Does the media prefer BMY or GILD?

Is BMY or GILD more profitable?

Do insiders and institutionals hold more shares of BMY or GILD?

Is BMY or GILD a better dividend stock?

Which has more volatility and risk, BMY or GILD?

Summary

How does Bristol Myers Squibb compare to Vertex Pharmaceuticals?

Do analysts recommend VRTX or BMY?

Does the media favor VRTX or BMY?

Is VRTX or BMY more profitable?

Which has better valuation and earnings, VRTX or BMY?

Do insiders and institutionals hold more shares of VRTX or BMY?

Which has more volatility & risk, VRTX or BMY?

Summary

How does Bristol Myers Squibb compare to AbbVie?

Do institutionals and insiders believe in ABBV or BMY?

Does the media refer more to ABBV or BMY?

Do analysts rate ABBV or BMY?

Is ABBV or BMY more profitable?

Is ABBV or BMY a better dividend stock?

Which has preferable earnings & valuation, ABBV or BMY?

Which has more risk & volatility, ABBV or BMY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY vs. The Competition

Bristol Myers Squibb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools